Giulia De Conti

Dr. Giulia De Conti

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Cell Reports
Verified
Journal Article
Open access
FJFleur Jochems
Fleur Jochems
BTBram Thijssen
Bram Thijssen
GCGiulia De Conti
Giulia De Conti
RJRobin Jansen
Robin Jansen
ZPZiva Pogacar
Ziva Pogacar
RBRené Bernards
René Bernards
Cellular senescence is characterized as a stable proliferation arrest that can be triggered by multiple stresses. Most knowledge about senescent cells is obtained from studies in primary cells. However, senescence features may be different in cancer cells, since the pathways that are involved in senescence induction are often deregulated in cancer. We report here a comprehensive analysis of the transcriptome and senolytic responses in a panel of 13 cancer cell lines rendered senescent by two distinct compounds. We show that in cancer cells, the response to senolytic agents and the composition of the senescence-associated secretory phenotype are more influenced by the cell of origin than by the senescence trigger. Using machine learning, we establish the SENCAN gene expression classifier for the detection of senescence in cancer cell samples. The expression profiles and senescence classifier are available as an interactive online Cancer SENESCopedia.

5 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GCGiulia De Conti
Giulia De Conti
MDMatheus Dias
Matheus Dias
RBRené Bernards
René Bernards
Designing specific therapies for drug-resistant cancers is arguably the ultimate challenge in cancer therapy. While much emphasis has been put on the study of genetic alterations that give rise to drug resistance, much less is known about the non-genetic adaptation mechanisms that operate during the early stages of drug resistance development. Drug-tolerant persister cells have been suggested to be key players in this process. These cells are thought to have undergone non-genetic adaptations that enable survival in the presence of a drug, from which full-blown resistant cells may emerge. Such initial adaptations often involve engagement of stress response programs to maintain cancer cell viability. In this review, we discuss the nature of drug-tolerant cancer phenotypes, as well as the non-genetic adaptations involved. We also discuss how malignant cells employ homeostatic stress response pathways to mitigate the intrinsic costs of such adaptations. Lastly, we discuss which vulnerabilities are introduced by these adaptations and how these might be exploited therapeutically.

20 May 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
Gaetano Ivan DellinoGaetano Ivan Dellino
Gaetano Ivan Dellino
FPFernando Palluzzi
Fernando Palluzzi
Andrea Maria ChiarielloAndrea Maria Chiariello
Andrea Maria Chiariello
RPRossana Piccioni
Rossana Piccioni
Simona BiancoSimona Bianco
Simona Bianco
Pier Giuseppe PelicciPier Giuseppe Pelicci
Pier Giuseppe Pelicci

22 November 2022 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
LWLiqin Wang
Liqin Wang
HJHaojie Jin
Haojie Jin
FJFleur Jochems
Fleur Jochems
SWSiying Wang
Siying Wang
CLCor Lieftink
Cor Lieftink
RBRené Bernards
René Bernards

26 March 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MDMatheus Henrique. Dias
Matheus Henrique. Dias
AFAnoek Friskes
Anoek Friskes
SWSiying Wang
Siying Wang
JNJoao M. Fernandes Neto
Joao M. Fernandes Neto
FGFrank van Gemert
Frank van Gemert
RBRené Bernards
René Bernards
Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of protein phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also suppressed the growth of patient-derived tumors in vivo. Remarkably, acquired resistance to this drug combination suppressed the ability of colon cancer cells to form tumors in vivo. Our data suggest that paradoxical activation of oncogenic signaling can result in tumor-suppressive resistance. Significance: A therapy consisting of deliberate hyperactivation of oncogenic signaling combined with perturbation of the stress responses that result from this is very effective in animal models of colon cancer. Resistance to this therapy is associated with loss of oncogenic signaling and reduced oncogenic capacity, indicative of tumor-suppressive drug resistance.

9 May 2022 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
ZPZiva Pogacar
Ziva Pogacar
KGKelvin Groot
Kelvin Groot
FJFleur Jochems
Fleur Jochems
MDMatheus Dos Santos Dias
Matheus Dos Santos Dias
AMAntonio Mulero-Sánchez
Antonio Mulero-Sánchez
RORodrigo Leite de Oliveira
Rodrigo Leite de Oliveira
Discovering biomarkers of drug response and finding powerful drug combinations can support the reuse of previously abandoned cancer drugs in the clinic. Indisulam is an abandoned drug that acts as a molecular glue, inducing degradation of splicing factor RBM39 through interaction with CRL4DCAF15. Here, we performed genetic and compound screens to uncover factors mediating indisulam sensitivity and resistance. First, a dropout CRISPR screen identified SRPK1 loss as a synthetic lethal interaction with indisulam that can be exploited therapeutically by the SRPK1 inhibitor SPHINX31. Moreover, a CRISPR resistance screen identified components of the degradation complex that mediate resistance to indisulam: DCAF15, DDA1, and CAND1. Last, we show that cancer cells readily acquire spontaneous resistance to indisulam. Upon acquiring indisulam resistance, pancreatic cancer (Panc10.05) cells still degrade RBM39 and are vulnerable to BCL-xL inhibition. The better understanding of the factors that influence the response to indisulam can assist rational reuse of this drug in the clinic.